ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / DFTX / dividends
RGC (38) TRLV (56) CRON (49) TLRY (19) ⌘ Pro Terminal →

Definium Therapeutics Inc. (DFTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$36.33 -4.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $35.98

Definium Therapeutics Inc. (DFTX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $4.88B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DFTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DFTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Definium Therapeutics Inc. (NASDAQ: DFTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $36.33 (-4.29% 1D, market cap $4.88B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DFTX ranks #297 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DFTX compare to RGC and TRLV in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), DFTX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.2%. By comparison, RGC (Regencell Bioscience Holdings Limited) holds a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.33B) and TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) posts a D+ grade (56/100 RQD, P/E N/A, ROIC 12.8%, cap $1.98B). Among the 5-stock peer group, DFTX leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DFTX?
▼

Per DFTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001813814), Definium Therapeutics Inc. generated $465.7M in revenue (+60.0% YoY), -$183.8M in net income, and -$131.6M in free cash flow against $440.1M in total assets and $40.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $35.98 (-0.96%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (8)Whales (11)SEC (14)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$52 Bull$35 Base$27 Bear
📬 FREE DFTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DFTX)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY DFTX SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (30% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)

20D Institutional Volume Accumulation (±9.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$34.24+3.7% Next Q
Q2 (-2Q)
42
Grade D$35.49+7.4% Next Q
Q3 (-1Q)
44
Grade D$38.10-4.6% Next Q
Current
47
Grade D$36.33-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DFTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DFTX currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($37.35) and Max Pain ($38.15) forces dealer call-delta covering toward $52.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DFTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DFTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DFTX)

  • ✓Walkthrough of DFTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DFTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +67.03%⚡ TESTING RESISTANCE
2026-11-03O $37.96H $37.96L $36.33C $36.33VOL 1.08M
RES: $38.41SUP: $29.64SMA50: $37.35SMA200: $29.93
$52.19$41.88$31.57$21.27$10.96RES $38.41SUP $29.64$36.332026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DFTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DFTX Butterfly Map → + Track DFTX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.5%/yr Implied 5Y Growth

vs. +5.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DFTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DFTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DFTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DFTX)

Health Care Rank #297 of 1016 ⚔️ RGC vs DFTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DFTX vs. RGC, TRLV, CRON, TLRY)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Definium Therapeutics Inc. (DFTX) ranks #297 by composite RQD confidence (47/100, grade D) and #166 by equity capitalization ($4.88B). Within this direct 5-issuer industry benchmark cohort, DFTX leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with DFTX at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DFTX ACTIVE
Definium Therapeutics Inc.
D 47/100 — — -32.2% -4.29% $4.88B Benchmark Subject
RGC
Regencell Bioscience Holdings Limited
D- 38/100 — — — -2.19% $3.33B /rgc-vs-dftx →
TRLV
Trulieve Cannabis Corp. Subordinate Voting Shares
D+ 56/100 — 60.2% 12.8% -3.02% $1.98B /trlv-vs-dftx →
CRON
Cronos Group Inc. Common Share
D 49/100 — 42.8% -4.5% -1.79% $1.22B /cron-vs-dftx →
TLRY
Tilray Brands Inc.
E 19/100 — 28.4% -3.9% -4.17% $373.9M /tlry-vs-dftx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001813814

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Definium Therapeutics Inc. (DFTX) reported GAAP revenue of $465.7M (+60.0% vs. FY2024 revenue of $291.0M , and +77.2% cumulative change since FY2023) , GAAP net income of -$183.8M, operating cash flow of -$131.6M, and free cash flow of -$131.6M (-66.3% YoY). On the balance sheet, DFTX closed FY2025 with $440.1M in total assets against $40.6M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $465.7M -$183.8M -$131.6M -$131.6M $440.1M $40.6M
FY2024 (FY) 2024-12-31 $291.0M -$108.7M -$79.1M -$79.1M $302.2M $21.9M
FY2023 (FY) 2023-12-31 $262.8M -$95.7M -$64.4M -$64.4M $2.81B $656.4M

3. DFTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DFTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Definium Therapeutics Inc. (NASDAQ: DFTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $36.33 (-4.29% 1D, market cap $4.88B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DFTX ranks #297 in composite RQD confidence.

How does DFTX compare to RGC and TRLV in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), DFTX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.2%. By comparison, RGC (Regencell Bioscience Holdings Limited) holds a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.33B) and TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) posts a D+ grade (56/100 RQD, P/E N/A, ROIC 12.8%, cap $1.98B). Among the 5-stock peer group, DFTX leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DFTX?

Per DFTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001813814), Definium Therapeutics Inc. generated $465.7M in revenue (+60.0% YoY), -$183.8M in net income, and -$131.6M in free cash flow against $440.1M in total assets and $40.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DFTX trading relative to its 50-day, 200-day, and 52-week technical levels?

DFTX last traded at $36.33 (-4.29% on volume of 1,076,712 shares), positioning the stock -2.73% below its 50-day simple moving average ($37.35) and +21.38% above its 200-day simple moving average ($29.93). Across its 52-week range of $10.47 to $49.70, DFTX sits at the 65.9% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($32.88 to $39.78).

Direct Sub-Reports: DFTX RQD Cockpit DFTX 12M Forecast DFTX Earnings & Move DFTX Dividends & DRIP DFTX Insiders & 13F DFTX Whale Options DFTX Profit Sankey DFTX News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DFTX — Definium Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:20:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating places DFTX at 52 out of 100, a D+ grade, labeled "Roarable Sell — Weak Fundamentals / Trim" per the Roarable RQD rating. Across its five pillars, the Fundamental Cash Engine scores 8 of 20, reflecting ROIC of -32.2% and FCF yield of -3.84%; this is the weakest pillar and indicates the business is not currently generating returns on invested capital or positive free cash flow. Whale 13F Flow scores 15 of 20 on institutional accumulation and options positioning, suggesting institutional interest is comparatively supportive. Insider Conviction scores 5 of 20 on SEC Form 4 and Congressional PTR cluster flow, the second-weakest pillar. Macro Regime Fit scores 10 of 20, tied to a Beta of 1.08 and sector sensitivity, meaning the stock is expected to move slightly more than the broader market. Forensic Balance Sheet scores 14 of 20, supported by an Altman Z-Score of 26, a Piotroski F-Score of 5 of 9, and Debt/Equity of 0.12 per the Roarable RQD rating. For a prospective investor, the upside case rests on institutional positioning and a strong balance sheet relative to obligations, while the valuation tradeoff is a forward P/E of 33 against negative EPS and negative free cash flow, meaning the market is pricing future earnings that the current financials do not yet show. The rating's own verdict is a trim signal, which an investor should weigh against the institutional and balance-sheet strengths described above.

Business

Definium Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Medicinal Chemicals and Botanical Products industry. Reported revenue is — in each of the FY 2023, FY 2024, and FY 2025 periods per the SEC financials. The market capitalization is $5.1B per the market data.

Recent Catalysts & News Wire Analysis

Per the news wire, the headlines carry the following flags. A Seeking Alpha item is flagged RED under RISK WATCH, titled "Outstanding Phase III Data De-Risks Pipeline, But Patience Required Ahead Of 2027," which references Phase III data and a 2027 timeline. An Investing.com item is flagged GREEN under CATALYST, asking why the stock is gaining. An Investing.com item referencing RBC Capital is flagged YELLOW under MARKET WIRE, describing a reiterated rating on trial data. A Yahoo Finance item, a TradingView item, and a Simply Wall St item are each flagged YELLOW under MARKET WIRE, covering fair value, estimates, and analyst predictions. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What is the specific nature and timing of the Phase III data referenced in the news wire, and what does the 2027 timeline depend on?
  • What revenue, if any, is expected from the company's pipeline, given — reported revenue across three periods?
  • What drove the decline in reported debt from $656.4M in FY 2023 to $40.6M in FY 2025, and how was it financed?
  • What is the company's cash runway given FY 2025 free cash flow of $-131.6M against $257.8M in cash?
  • Why is the P/E (TTM) unavailable while forward P/E is 33, and how does the market reconcile that against negative EPS?

DFTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Definium Therapeutics Inc. (DFTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DFTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DFTX Bull vs. Bear Conversation Board — What's Your Call at $36.33?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DFTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DFTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $46.50 (+28.0%)
📌 Pinned Debate

Institutional accumulation scores 15 of 20 and the Forensic Balance Sheet scores 14 of 20, with Debt/Equity of 0.12 and an Altman Z-Sco

Picked up a starter position in DFTX in my $100K Virtual Cash book at $36.33. Institutional accumulation scores 15 of 20 and the Forensic Balance Sheet scores 14 of 20, with Debt/Equity of 0.12 and an Altman Z-Score of 26.. Trading inside a $10.47–$49.70 52-week range with -3.84% FCF yield gives solid downside support if Medicinal Chemicals and Botanical Products multiples expand this quarter.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 47/100 quality, though with 1.08 beta I'm scaling in with half-size at $36.33 and keeping dry powder in case we test $33.79.

BE BearTrap_Alert Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $28.70 (-21.0%)
Spot @ $36.33

ROIC of -32.2%, FCF yield of -3.84%, and negative FY 2025 free cash flow of $-131.6M leave the Fundamental Cash Engine at 8 of 20.

Here is the bear case nobody on the bull side wants to address on DFTX: ROIC of -32.2%, FCF yield of -3.84%, and negative FY 2025 free cash flow of $-131.6M leave the Fundamental Cash Engine at 8 of 20.. At 33.0x forward P/E, even a small guidance miss in Medicinal Chemicals and Botanical Products triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%